iopromide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 1468 73334-07-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iopromide
  • iopromidum
  • Molecular weight: 791.12
  • Formula: C18H24I3N3O8
  • CLOGP: -1.67
  • LIPINSKI: 3
  • HAC: 11
  • HDO: 6
  • TPSA: 168.66
  • ALOGS: -3.34
  • ROTB: 11
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 97 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3227.25 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.99 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.60 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,ZAP70 35
kinase-selectivity-class AURKA,AURKB,AXL,BRAF,CAMK2D,CDK16,CDK4,CDK6,CDK9,CLK4,DYRK1B,EIF2AK3,EPHB4,GRK2,GSK3A,GSK3B,KIT,MAP2K6,MAP3K21,MAP4K1,MAPK7,MAPK8,PDK1,PIK3CB,PIK3CD,PRKDC,SIK2,SIK3,STK33,SYK,TEK 31
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
May 10, 1995 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 548.14 56.68 167 6620 31450 90590210
Contrast media allergy 489.92 56.68 97 6690 2984 90618676
Blood pressure decreased 431.36 56.68 174 6613 74721 90546939
Urticaria 312.81 56.68 226 6561 312508 90309152
Erythema 295.91 56.68 194 6593 229052 90392608
Contrast encephalopathy 239.31 56.68 35 6752 150 90621510
Contrast media reaction 226.92 56.68 44 6743 1207 90620453
Respiratory rate increased 204.11 56.68 67 6720 15934 90605726
Dyspnoea 195.65 56.68 281 6506 880674 89740986
Eyelid oedema 187.11 56.68 58 6729 11476 90610184
Loss of consciousness 183.70 56.68 120 6667 140118 90481542
Pruritus 181.39 56.68 212 6575 541313 90080347
Sneezing 173.62 56.68 70 6717 29799 90591861
Blood pressure immeasurable 166.35 56.68 35 6752 1457 90620203
Oxygen saturation decreased 165.72 56.68 102 6685 107381 90514279
Laryngeal oedema 161.28 56.68 46 6741 6835 90614825
Face oedema 136.70 56.68 55 6732 23263 90598397
Cyanosis 128.42 56.68 50 6737 19405 90602255
Dysphonia 118.36 56.68 68 6719 63016 90558644
Unresponsive to stimuli 113.74 56.68 56 6731 38065 90583595
Anaphylactic reaction 112.26 56.68 74 6713 87450 90534210
Hyperaemia 105.98 56.68 27 6760 2615 90619045
Flushing 97.23 56.68 68 6719 88423 90533237
Chest discomfort 90.15 56.68 78 6709 138287 90483373
Throat irritation 90.01 56.68 52 6735 48643 90573017
Papule 84.16 56.68 29 6758 7973 90613687
Urinary incontinence 77.19 56.68 43 6744 37523 90584137
Heart rate increased 74.23 56.68 64 6723 112838 90508822
Amaurosis 72.89 56.68 16 6771 814 90620846
Tachypnoea 68.63 56.68 33 6754 21276 90600384
Pallor 67.18 56.68 38 6749 34127 90587533
Pulse absent 63.89 56.68 22 6765 6033 90615627
Chills 63.78 56.68 63 6724 131918 90489742
Ocular hyperaemia 62.19 56.68 36 6751 33762 90587898
Lip oedema 61.44 56.68 20 6767 4619 90617041
Foaming at mouth 60.11 56.68 15 6772 1335 90620325
Rash erythematous 60.00 56.68 45 6742 65059 90556601
Nasal obstruction 59.12 56.68 17 6770 2595 90619065
Heart rate decreased 58.46 56.68 41 6746 53464 90568196
Cold sweat 58.43 56.68 26 6761 14055 90607605
Asphyxia 56.75 56.68 21 6766 7082 90614578

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 510 56.12 170 5663 23347 42592155
Contrast media allergy 489.46 56.12 86 5747 701 42614801
Urticaria 353.45 56.12 181 5652 73855 42541647
Blood pressure decreased 344.84 56.12 165 5668 58167 42557335
Erythema 227.10 56.12 156 5677 108637 42506865
Contrast encephalopathy 221.40 56.12 35 5798 134 42615368
Pruritus 219.31 56.12 191 5642 188580 42426922
Contrast media reaction 216.89 56.12 46 5787 1070 42614432
Respiratory rate increased 170 56.12 62 5771 11000 42604502
Sneezing 169.99 56.12 54 5779 6309 42609193
Blood pressure immeasurable 160.06 56.12 35 5798 943 42614559
Oxygen saturation decreased 149.58 56.12 99 5734 64588 42550914
Hyperhidrosis 130.40 56.12 104 5729 90408 42525094
Chest discomfort 113.33 56.12 83 5750 63533 42551969
Dyspnoea 112.34 56.12 209 5624 442412 42173090
Loss of consciousness 111.88 56.12 96 5737 92258 42523244
Cyanosis 111.79 56.12 50 5783 14981 42600521
Heart rate increased 95.98 56.12 70 5763 53185 42562317
Eyelid oedema 95.24 56.12 34 5799 5661 42609841
Flushing 91.14 56.12 59 5774 36969 42578533
Alveolar lung disease 89.50 56.12 19 5814 443 42615059
Pulmonary interstitial emphysema syndrome 85.76 56.12 19 5814 544 42614958
Tachypnoea 83.25 56.12 46 5787 21616 42593886
Anaphylactic reaction 72.07 56.12 54 5779 42689 42572813
Oxygen saturation immeasurable 70.45 56.12 11 5822 38 42615464
Pallor 68.54 56.12 45 5788 28841 42586661
Face oedema 63.68 56.12 33 5800 13633 42601869
Unresponsive to stimuli 62.78 56.12 44 5789 31359 42584143
Nephropathy toxic 62.62 56.12 35 5798 16803 42598699
Diffuse alveolar damage 61.03 56.12 20 5813 2572 42612930
Cold sweat 60.50 56.12 30 5803 11300 42604202
Hyperaemia 58.02 56.12 17 5816 1509 42613993

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 1036.25 50.32 337 12330 51209 110525423
Contrast media allergy 949.56 50.32 184 12483 3239 110573393
Blood pressure decreased 766.11 50.32 335 12332 114756 110461876
Urticaria 525.39 50.32 369 12298 318488 110258144
Erythema 472.23 50.32 334 12333 291113 110285519
Contrast encephalopathy 439.30 50.32 69 12598 313 110576319
Contrast media reaction 431.87 50.32 90 12577 2308 110574324
Respiratory rate increased 372.92 50.32 131 12536 24952 110551680
Pruritus 359.32 50.32 384 12283 581176 109995456
Oxygen saturation decreased 301.10 50.32 200 12467 156782 110419850
Sneezing 299.40 50.32 119 12548 31865 110544767
Blood pressure immeasurable 290.10 50.32 65 12602 2358 110574274
Loss of consciousness 280.83 50.32 209 12458 196097 110380535
Eyelid oedema 274.69 50.32 92 12575 15170 110561462
Dyspnoea 268.03 50.32 463 12204 1106409 109470223
Cyanosis 241.72 50.32 100 12567 29641 110546991
Chest discomfort 187.85 50.32 157 12510 173691 110402941
Laryngeal oedema 183.94 50.32 61 12606 9746 110566886
Anaphylactic reaction 175.17 50.32 127 12540 114173 110462459
Flushing 173.44 50.32 122 12545 104614 110472018
Face oedema 167.12 50.32 80 12587 33389 110543243
Unresponsive to stimuli 164.06 50.32 98 12569 63692 110512940
Hyperhidrosis 163.82 50.32 150 12517 187148 110389484
Tachypnoea 157.64 50.32 81 12586 39314 110537318
Heart rate increased 155.53 50.32 130 12537 143704 110432928
Hyperaemia 155.31 50.32 43 12624 3730 110572902
Nephropathy toxic 150.46 50.32 70 12597 27408 110549224
Dysphonia 145.94 50.32 97 12570 75832 110500800
Pallor 125.38 50.32 79 12588 56388 110520244
Cold sweat 120.22 50.32 56 12611 21975 110554657
Urinary incontinence 115.51 50.32 71 12596 48516 110528116
Papule 109.95 50.32 42 12625 10091 110566541
Oxygen saturation immeasurable 109.93 50.32 17 12650 68 110576564
Amaurosis 103.22 50.32 26 12641 1563 110575069
Incorrect drug administration rate 102.23 50.32 34 12633 5474 110571158
Oropharyngeal discomfort 98.57 50.32 39 12628 10288 110566344
Throat irritation 97.08 50.32 66 12601 53486 110523146
Rash erythematous 96.83 50.32 78 12589 81754 110494878
Diarrhoea 92.88 50.32 11 12656 1139494 109437138
Nasal obstruction 92.54 50.32 28 12639 3322 110573310
Sensation of foreign body 89.93 50.32 34 12633 7941 110568691
Pulmonary interstitial emphysema syndrome 88.71 50.32 19 12648 556 110576076
Conjunctival hyperaemia 84.85 50.32 30 12637 5801 110570831
Alveolar lung disease 84.48 50.32 19 12648 700 110575932
Drug reaction with eosinophilia and systemic symptoms 82.09 50.32 71 12596 82024 110494608
Pulse absent 81.77 50.32 35 12632 11257 110565375
Heart rate decreased 81.60 50.32 71 12596 82685 110493947
Chills 80.46 50.32 104 12563 190476 110386156
Dysphoria 78.30 50.32 29 12638 6399 110570233
Ocular hyperaemia 77.40 50.32 51 12616 39235 110537397
Pneumonia 75.12 50.32 7 12660 876707 109699925
Asphyxia 74.05 50.32 35 12632 14180 110562452
Lip oedema 73.58 50.32 29 12638 7571 110569061
Off label use 71.33 50.32 42 12625 1500143 109076489
Hypoaesthesia oral 71.01 50.32 36 12631 16966 110559666
Pulse abnormal 70.63 50.32 24 12643 4125 110572507
Suffocation feeling 68.75 50.32 20 12647 2071 110574561
Condition aggravated 68.24 50.32 4 12663 734832 109841800
Foaming at mouth 67.13 50.32 20 12647 2250 110574382
Dizziness 65.74 50.32 202 12465 697991 109878641
Lip swelling 65.73 50.32 51 12616 50616 110526016
Conjunctival oedema 65.26 50.32 18 12649 1538 110575094
Eye oedema 64.74 50.32 20 12647 2542 110574090
Acute generalised exanthematous pustulosis 60.15 50.32 35 12632 21629 110555003
Arthralgia 59.90 50.32 9 12658 779623 109797009
Throat tightness 57.67 50.32 40 12627 33449 110543183
Swelling of eyelid 56.15 50.32 23 12644 6630 110570002
Diffuse alveolar damage 55.77 50.32 20 12647 4027 110572605
Vomiting 53.64 50.32 226 12441 910449 109666183
Fatigue 52.33 50.32 38 12629 1215920 109360712
Palpitations 52.28 50.32 77 12590 159135 110417497
Laryngeal discomfort 51.79 50.32 13 12654 770 110575862
Angioedema 51.64 50.32 60 12607 98440 110478192
Hypotension 50.56 50.32 153 12514 523696 110052936

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08AB05 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA N0000010258 X-Ray Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000180185 Radiographic Contrast Agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:37338 radioopaque medium
CHEBI has role CHEBI:50909 nephrotoxic agent
CHEBI has role CHEBI:78298 environmental contaminant

Related Drugs by ATC class:

V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media 11 drugs
iobitridoliodixanoliohexoliomeproliopamidoliopentoliotrolanioversolioxaglic acidioxilanmetrizamide

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.84 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020929 VUID
N0000148411 NUI
D01893 KEGG_DRUG
4020929 VANDF
C0063817 UMLSCUI
CHEBI:63578 CHEBI
CHEMBL1725 ChEMBL_ID
DB09156 DRUGBANK_ID
C038192 MESH_SUPPLEMENTAL_RECORD_UI
4919 INN_ID
712BAC33MZ UNII
3736 PUBCHEM_CID
27781 RXNORM
4907 MMSL
7868 MMSL
d03840 MMSL
003739 NDDF
353903006 SNOMEDCT_US
395756007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-342 INJECTION 240 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-342 INJECTION 240 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-344 INJECTION 300 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-344 INJECTION 300 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-344 INJECTION 300 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-346 INJECTION 370 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-346 INJECTION 370 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-346 INJECTION 370 mg INTRA-ARTERIAL NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-347 INJECTION 300 mg INTRAVENOUS NDA 27 sections
Ultravist HUMAN PRESCRIPTION DRUG LABEL 1 50419-348 INJECTION 370 mg INTRA-ARTERIAL NDA 27 sections